全文获取类型
收费全文 | 89978篇 |
免费 | 7633篇 |
国内免费 | 3212篇 |
专业分类
耳鼻咽喉 | 982篇 |
儿科学 | 2154篇 |
妇产科学 | 1330篇 |
基础医学 | 9746篇 |
口腔科学 | 2937篇 |
临床医学 | 7733篇 |
内科学 | 7953篇 |
皮肤病学 | 832篇 |
神经病学 | 2708篇 |
特种医学 | 5349篇 |
外国民族医学 | 52篇 |
外科学 | 18673篇 |
综合类 | 13558篇 |
现状与发展 | 19篇 |
预防医学 | 2638篇 |
眼科学 | 635篇 |
药学 | 5530篇 |
53篇 | |
中国医学 | 2517篇 |
肿瘤学 | 15424篇 |
出版年
2024年 | 205篇 |
2023年 | 1182篇 |
2022年 | 2607篇 |
2021年 | 3354篇 |
2020年 | 2737篇 |
2019年 | 2494篇 |
2018年 | 2562篇 |
2017年 | 2685篇 |
2016年 | 3167篇 |
2015年 | 3460篇 |
2014年 | 5394篇 |
2013年 | 5486篇 |
2012年 | 4839篇 |
2011年 | 5453篇 |
2010年 | 4474篇 |
2009年 | 4693篇 |
2008年 | 4655篇 |
2007年 | 4923篇 |
2006年 | 4507篇 |
2005年 | 4204篇 |
2004年 | 3566篇 |
2003年 | 3009篇 |
2002年 | 2602篇 |
2001年 | 2324篇 |
2000年 | 2088篇 |
1999年 | 1807篇 |
1998年 | 1533篇 |
1997年 | 1450篇 |
1996年 | 1218篇 |
1995年 | 1127篇 |
1994年 | 960篇 |
1993年 | 782篇 |
1992年 | 658篇 |
1991年 | 554篇 |
1990年 | 447篇 |
1989年 | 406篇 |
1988年 | 409篇 |
1987年 | 343篇 |
1986年 | 302篇 |
1985年 | 336篇 |
1984年 | 291篇 |
1983年 | 168篇 |
1982年 | 252篇 |
1981年 | 206篇 |
1980年 | 164篇 |
1979年 | 179篇 |
1978年 | 135篇 |
1977年 | 109篇 |
1976年 | 84篇 |
1973年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
后路治疗胸腰椎爆裂骨折 总被引:3,自引:0,他引:3
目的:探讨后路环椎管减压,椎弓根钉系统复位固定并植骨治疗胸腰椎爆裂骨折的疗效。方法:1996-2001年,环椎环椎管减压,结合具有钉杆角的椎弓根钉系统复位固定,并横突及小关节突间植骨或椎间植骨治疗128例病人,从伤椎椎体前后缘高度恢复,Cobb角矫正度及神经功能恢复情况评价疗效。结果:128例病人脊髓神经损害无加重,神经功能有不同程度恢复;伤椎高度恢复理想,Cobb角明显减少,植骨融合成功108例(占84.4%),术后部分病例出现伤椎复位度丢失现象。结论:后路环椎管减压内固定治疗胸腰椎骨折效果好,应重视植骨融合以获得良好稳定性。 相似文献
62.
鼻部源性突眼的CT分析 总被引:1,自引:0,他引:1
目的:为了提高对鼻部源性突眼的认识。材料和方法:本文19例鼻部源性突眼,其中鼻咽癌7例,鼻咽纤维血管瘤2例,鼻腔纤维血管瘤、恶性肉芽肿和嗅神经母细胞瘤各1例,上颌窦癌和软骨肉瘤各2例,上颌窦恶性肉芽肿、纤维肉瘤和恶性纤维组织细胞瘤各1例,全部病例均作轴位CT扫描,12例加作增强扫描,详细分析了它们CT表现。结果:源于鼻咽的放疗前鼻咽癌和纤维血管瘤,其病变主要位于鼻咽腔和咽旁,后者显著增强并有钙斑,与前者不同;源于上颌窦的肿瘤,病变占据上颌窦的全部或大部分,软骨肉瘤有钙斑且无强化,易与其它肿瘤区别,它们破坏上颌窦顶部进入眼眶;鼻腔嗅神经母细胞瘤在鼻腔和筛窦形成肿块,破坏筛骨眶板侵入眼眶。结论:根据CT所见,可判断突眼原因。 相似文献
63.
Localized proton magnetic resonance spectroscopy of a cerebellar tumor in a two-year-old child 总被引:1,自引:0,他引:1
B. Wilken G. Helms H. J. Christen J. Bhnk J. Frahm F. Hanefeld 《Child's nervous system》1996,12(10):626-629
Noninvasive localized proton magnetic resonance spectroscopy (MRS) was used for differential diagnosis of a focal brain lesion in a 2.5-year-old girl. The clinical signs were a mild head tilt and neck pain. Magnetic resonance imaging (MRI) revealed a lesion in the right hemisphere of the cerebellum, but its nature remained obscure. In this lesion quantitative determinations of cerebral metabolites by fully relaxed, short-echo-time proton MRS revealed markedly lowered N-acetylaspartate (NAA) and pronounced elevations of choline-containing compounds (Cho) and myo-inositol (Ins), whereas metabolite concentrations in cortical gray matter and white matter were within normal ranges. The metabolite pattern of the lesion indicated loss of vital neuroaxonal tissue (low NAA) and enhanced glial proliferation (high Cho and Ins), which, together with the MRI morphology, suggested a brain tumor. The diagnosis was established by neurosurgical exploration and total extirpation of the tumor. Histology confirmed an astrocytoma (WHO II). After 2 weeks' recovery the child was discharged with no neurological signs. 相似文献
64.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
65.
目的 :探讨联合菌苗防治肿瘤的作用。方法采用动物体内实验 ,动物为封闭群KM小鼠 ,菌株为 2 6 0 0 3- 2 1、4 482 4 - 3及 932 0 1- 3,瘤种为S180 。所有实验小鼠接种S180 后 ,按随机对照试验设计分成 5组 ,即三个不同的单价菌苗组、一个联合菌苗组及一个对照组 ,同期观察联合菌苗对S180 增长的影响。结果 :三个不同的单价菌苗组及联合菌苗组的平均瘤重均比对照组低 ,联合菌苗组的平均瘤重比单价菌苗组的更低 ,差异均有高度统计学意义 (P <0 .0 1~ 0 .0 0 1) ;三个不同单价菌苗组的抑瘤率分别为 5 0 .6 %、4 8.3%、4 5 .5 % ,联合菌苗组抑瘤率为 75 .0 %。结论 :实验所选用的菌苗能抑制S180 的增长 ,联合菌苗的效果更好 相似文献
66.
分析原发性腹膜后恶性肿瘤12例。83%以腹块和腹痛为主要症状,体征中腹块占91.5%,以恶性淋巴瘤居首位占61%。全组完全切除率为58%,行脏器联合切除占25%。完全切除加放疗、化疗3年存活率为28.5%,部分切除及活检未给其它治疗者5例预后差,均1年内死亡,差别显著。 相似文献
67.
T. M. Skerry M.D. M.R.C.V.S. R. Suswillo A. J. El Haj N. N. Ali R. A. Dodds L. E. Lanyon 《Calcified tissue international》1990,46(5):318-326
Summary Previous studies of Alcian blue-induced birefringence in adult avian cortical bone showed that a short period of intermittent
loading rapidly produces an increased level of orientation of proteoglycans within the bone tissue. In the absence of further
loading, this persists for over 24 hours. We have proposed that this phenomenon could provide a means for “capturing” the
effects of transient strains, and so provide a persistent, constantly updated strain-related influence on osteocyte populations
related to the bones' averaged recent strain history, in effect, a “strain memory” in bone tissue. In our present study, we
use the Alcian blue-induced birefringence technique to demonstrate that proteoglycan orientation also occurs after intermittent
loading of both cortical and cancellous mammalian bonein vivo andin vitro. We also show that the change in birefringence is proportional to the magnitude of the applied strain, and that the reorientation
occurs rapidly, reaching a maximal value after only 50 loading cycles. Examination of electron micrographs of bone tissue
after staining with cupromeronic blue allows direct visualization and quantification of the change in proteoglycan orientation
produced by loading. This shows that intermittent loading is associated with a realignment of the proteoglycan protein cores,
bringing them some 5 degrees closer to the direction of collagen fibrils in the bone matrix. 相似文献
68.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
69.
卵巢恶性肿瘤与血小板增多关系分析 总被引:1,自引:0,他引:1
李洁华 《中国现代医药杂志》2005,7(5):48-49
目的探讨卵巢恶性肿瘤伴发血小板增多的临床规律。方法回顾分析98例卵巢恶性肿瘤患者的临床资料,26例合并血小板增多。结果血小板增多占26.5%,其中晚期(Ⅲ+Ⅳ期)占88.46%,晚期患者血小板偏高明显增多,且肿瘤切除后血小板下降。结论卵巢恶性肿瘤伴发血小板增多晚期患者多见,预后差,血小板增多可作为判断卵巢肿瘤恶性程度及术后随访的指标。 相似文献
70.
Paul Steinbok Ken Poskitt D. Douglas Cochrane O. Olof Flodmark 《Child's nervous system》1991,7(1):16-20
Enhanced and non-enhanced computed tomography (CT) brain scans were performed within 72 h of surgery on 21 children in whom brain tumors had been resected totally or subtotally, and scans were repeated at varying intervals thereafter. Biopsies of the resection margins were performed in 12 patients at the end of the surgical procedure. The immediate CT scan showed enhancement in the resection margin in 13 of the 21 patients and in 9 of the 13, the enhancement disappeared on follow-up scans. There was discordance between the results of immediate CT scan examination and the biopsies of the resection margins in 7 of the 12 cases. The advantages and disadvantages of an immediate postoperative scan versus a more delayed CT scan are discussed. 相似文献